Melatonin and ulcerative colitis

Evidence, biological mechanisms, and future research

Paul Terry, Francois Villinger, George A. Bubenik, Shanti V. Sitaraman

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease that afflicts up to 1 million people in the US. Current treatments for UC are mostly nonspecific, not always effective, and often accompanied by serious side effects. Therefore, there is considerable interest in finding alternative and more tolerable treatments for this disease. Physiologic data suggest that melatonin is an important regulator of both inflammation and motility in the gastrointestinal tract, and data from in vitro studies, animal experiments, and limited studies in humans suggest that supplemental melatonin may have an ameliorative effect on colitis. In this review we summarize the evidence regarding melatonin as a possible therapeutic agent in UC and discuss possible biological mechanisms and directions for future research.

Original languageEnglish (US)
Pages (from-to)134-140
Number of pages7
JournalInflammatory bowel diseases
Volume15
Issue number1
DOIs
StatePublished - Jun 1 2009

Fingerprint

Melatonin
Ulcerative Colitis
Colitis
Inflammatory Bowel Diseases
Gastrointestinal Tract
Inflammation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Cite this

Melatonin and ulcerative colitis : Evidence, biological mechanisms, and future research. / Terry, Paul; Villinger, Francois; Bubenik, George A.; Sitaraman, Shanti V.

In: Inflammatory bowel diseases, Vol. 15, No. 1, 01.06.2009, p. 134-140.

Research output: Contribution to journalReview article

Terry, Paul ; Villinger, Francois ; Bubenik, George A. ; Sitaraman, Shanti V. / Melatonin and ulcerative colitis : Evidence, biological mechanisms, and future research. In: Inflammatory bowel diseases. 2009 ; Vol. 15, No. 1. pp. 134-140.
@article{803f8eb093854729aa87e4637f4a1dd6,
title = "Melatonin and ulcerative colitis: Evidence, biological mechanisms, and future research",
abstract = "Ulcerative colitis (UC) is an inflammatory bowel disease that afflicts up to 1 million people in the US. Current treatments for UC are mostly nonspecific, not always effective, and often accompanied by serious side effects. Therefore, there is considerable interest in finding alternative and more tolerable treatments for this disease. Physiologic data suggest that melatonin is an important regulator of both inflammation and motility in the gastrointestinal tract, and data from in vitro studies, animal experiments, and limited studies in humans suggest that supplemental melatonin may have an ameliorative effect on colitis. In this review we summarize the evidence regarding melatonin as a possible therapeutic agent in UC and discuss possible biological mechanisms and directions for future research.",
author = "Paul Terry and Francois Villinger and Bubenik, {George A.} and Sitaraman, {Shanti V.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1002/ibd.20527",
language = "English (US)",
volume = "15",
pages = "134--140",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Melatonin and ulcerative colitis

T2 - Evidence, biological mechanisms, and future research

AU - Terry, Paul

AU - Villinger, Francois

AU - Bubenik, George A.

AU - Sitaraman, Shanti V.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Ulcerative colitis (UC) is an inflammatory bowel disease that afflicts up to 1 million people in the US. Current treatments for UC are mostly nonspecific, not always effective, and often accompanied by serious side effects. Therefore, there is considerable interest in finding alternative and more tolerable treatments for this disease. Physiologic data suggest that melatonin is an important regulator of both inflammation and motility in the gastrointestinal tract, and data from in vitro studies, animal experiments, and limited studies in humans suggest that supplemental melatonin may have an ameliorative effect on colitis. In this review we summarize the evidence regarding melatonin as a possible therapeutic agent in UC and discuss possible biological mechanisms and directions for future research.

AB - Ulcerative colitis (UC) is an inflammatory bowel disease that afflicts up to 1 million people in the US. Current treatments for UC are mostly nonspecific, not always effective, and often accompanied by serious side effects. Therefore, there is considerable interest in finding alternative and more tolerable treatments for this disease. Physiologic data suggest that melatonin is an important regulator of both inflammation and motility in the gastrointestinal tract, and data from in vitro studies, animal experiments, and limited studies in humans suggest that supplemental melatonin may have an ameliorative effect on colitis. In this review we summarize the evidence regarding melatonin as a possible therapeutic agent in UC and discuss possible biological mechanisms and directions for future research.

UR - http://www.scopus.com/inward/record.url?scp=61949356612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949356612&partnerID=8YFLogxK

U2 - 10.1002/ibd.20527

DO - 10.1002/ibd.20527

M3 - Review article

VL - 15

SP - 134

EP - 140

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -